At JADPRO Live 2023, presenters discussed the implications of biomarker testing, pivotal clinical trials leading to recent FDA approvals, and evidence-based best practices for monitoring and managing adverse events associated with molecular targeted and combination therapies for patients with metastatic non-small cell lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11406318 | PMC |
| http://dx.doi.org/10.6004/jadpro.2024.15.3.7 | DOI Listing |
Publication Analysis
Top Keywords
patients metastatic
8
metastatic non-small
8
non-small cell
8
cell lung
8
lung cancer
8
advancing precision-targeted
4
precision-targeted treatment
4
treatment patients
4
cancer jadpro
4
jadpro live
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!